The Patent Reform Act of 2007 is stirring debate, not only in both houses of Congress, but also within the pharmaceutical, biotechnology, software, and electronics industries. Nanotechnology companies too must be aware of what is at stake. In this article, Washington, DC patent attorney Stephen Maebius discusses the potential impact of the pending legislation on nanotechnology. The proposed changes would affect everything from who is entitled to receive a patent (first-to-invent or first-to-file) all the way to how infringement damages are calculated. Because they rely so heavily on the value of their patent portfolio, nanotech companies should form a collective voice to communicate a position in this important debate.
Author(s)
Related Insights
April 3, 2026
Energy Current
Texas Legislature Sets Its Sights on Data Centers and AI: What You Need to Know
Texas House and Senate leadership recently released their interim charges, which serve as "homework assignments" for legislative…
April 3, 2026
Foley Viewpoints
For Your Eyes Only? Not Quite: Shadow AI in the Workplace
While many companies are still developing governance frameworks for authorized AI tools, an emerging risk has quietly surfaced: employees using unauthorized transcription tools without the company’s or participants’ consent.
April 3, 2026
Manufacturing Industry Advisor
Connecticut Appellate Court Narrows Scope of Petroleum “Franchise” Protections for Gas Station Operators
The Appellate Court of Connecticut affirmed a trial court’s judgment in favor of a petroleum distributor/lessor, holding that convenience…